The applicability of blood recalcification time as a laboratory test to assess and thereby regulate heparin anticoagulation was evaluated. Normal values for blood recalcification time ranged from 65 to 135 seconds, with a mean and standard deviation of 99 and 12 seconds, respectively. Duplicate determinations showed a mean variation of 5%. Blood recalcification times increased as a linear function of increasing heparin concentrations in vitro. Comparison with whole-blood clotting times revealed reasonably good correlation between the two tests. For whole-blood clotting times of 20 to 45 minutes the corresponding blood recalcification times were 142 to 212 seconds. The therapeutic range is often considered to be twice the normal range (130-270 seconds). In-vivo study revealed the peak blood recalcification time in the first sample collected 30 minutes after heparin injection, and a progressive decline thereafter to the pre-injection level during the subsequent 4 hours. The blood recalcification time is a simple, precise and clinically useful test to monitor heparin therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ajcp/65.3.390 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ethylenediamine-modified alginate - A hemocompatible platform for polymer-drug conjugates.
Int J Biol Macromol
January 2025
Institute of Chemistry of Komi Scientific Centre of the Ural Branch of the Russian Academy of Sciences, Pervomayskaya st. 48, Syktyvkar 167000, Komi Republic, Russian Federation. Electronic address:
The study is dedicated to the synthesis, rheological properties, hemocompatibility, and further modification of water-soluble derivatives of sodium alginate containing fragments of ethylenediamine (Alg-EDA). Alg-EDA with an equal ratio of amide/amine groups and varying degrees of substitution were synthesized by the carbodiimide method. The influence of the molecular weight of Alg-EDA on the attachment of bioactive molecules such as hydroxybenzoic and ferulic acids was determined.
View Article and Find Full Text PDFKallikrein inhibitor derived from immunoglobulin heavy chain junction region possesses anti-thromboinflammation potential.
Pharmacol Res
November 2024
Engineering Laboratory of Peptides of Chinese Academy of Sciences, Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, National Resource Center for Non-Human Primates, National Research Facility for Phenotypic & Genetic Analysis of Model Animals (Primate Facility), Key Laboratory of Genetic Evolution & Animal Models, Sino-African Joint Research Center, and New Cornerstone Science Laboratory, Kunming Institute of Zoology, the Chinese Academy of Sciences, No.17 Longxin Road, Kunming, Yunnan, 650201, P. R. China. Electronic address:
Article Synopsis
- - Influenza vaccination is linked to lower rates of cardiovascular issues and overall mortality, but the role of related immunoglobulins isn't fully understood.
- - A specific immunoglobulin heavy chain junction sequence (SD6) was found to inhibit plasma kallikrein activity, potentially reducing thromboinflammatory responses and stroke damage.
- - In tests on mice, SD6 decreased thrombosis and cerebral injury without increasing bleeding risk, indicating its promise as a treatment for conditions related to blood inflammation.
Development of substrate-independent heparin coating to mitigate surface-induced thrombogenesis: efficacy and mechanism.
J Mater Chem B
October 2024
College of Polymer Science and Engineering, State Key Laboratory of Polymer Materials Engineering, Sichuan University, Chengdu, 610065, People's Republic of China.
Heparin coatings are widely applied on blood-contact materials to reduce the use of anticoagulants during blood treatment. However, the previous heparin coatings formed covalent binding or electrostatic bonding commonly require complex surface premodification, and the blood coagulation pathway was significantly inhibited to potentially increase the bleeding risk. This contradicts the intended purpose and deviates from the anticoagulation mechanism of the heparin coatings.
View Article and Find Full Text PDFSpatiotemporally Controlled Release of Etamsylate from Bioinspired Peptide-Functionalized Nanoparticles Arrests Bleeding Rapidly and Improves Clot Stability in a Rabbit Internal Hemorrhage Model.
ACS Biomater Sci Eng
August 2024
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Kolkata 700054, India.
Achieving rapid clotting and clot stability are important unmet goals of clinical management of noncompressible hemorrhage. This study reports the development of a spatiotemporally controlled release system of an antihemorrhagic drug, etamsylate, in the management of internal hemorrhage. Gly-Arg-Gly-Asp-Ser (GRGDS) peptide-functionalized chitosan nanoparticles, with high affinity to bind with the GPIIa/IIIb receptor of activated platelets, were loaded with the drug etamsylate (etamsylate-loaded GRGDS peptide-functionalized chitosan nanoparticles; EGCSNP).
View Article and Find Full Text PDFThe purification of a fibrinolytic enzyme from the fruiting bodies of wild-growing medicinal mushroom, Pycnoporus coccineus was achieved through a two-step procedure, resulting in its homogeneity. This purification process yielded a significant 4.13-fold increase in specific activity and an 8.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!